Related Experiment Video

Updated: Jul 5, 2026

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
06:02

Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants

Published on: November 28, 2025

[Glutaric aciduria type 1: clinical presentations, diagnostics and treatment.]

S V Mikhaĭlova1, E Iu Zakharova, M Iu Bobylova

  • 1Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta Gosudarstvennogo obrazovatel'nogo uchrezhdeniia vysshego professional'nogo obrazovaniia; Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet Ministerstva zdravookhraneniia RF, Moskva; Rossiĭskaia detskaia klinicheskaia bol'nitsa, Moskva; GU Mediko-geneticheskiĭ nauchnyĭ tsentr, Moskva.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|May 15, 2008
PubMed

Insights

Glutaric aciduria type I is a rare neurometabolic disorder affecting infants, causing basal ganglia damage and movement issues. Early diagnosis via mass spectrometry and treatment with dietary changes are crucial.

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Genetics

Background:

  • Glutaric aciduria type I (GA-I) is a rare, inherited neurometabolic disease.
  • It typically manifests in the first year of life, causing progressive basal ganglia damage.
  • This damage leads to severe extrapyramidal movement disorders.

Purpose of the Study:

  • To report the first cases of Glutaric aciduria type I in the Russian population.
  • To compare clinical observations with existing literature data.
  • To highlight diagnostic and treatment strategies for GA-I.

Main Methods:

  • Clinical case observations.
  • Urine and blood sample analysis using tandem mass spectrometry and gas chromatography.
  • Literature review and data comparison.

Main Results:

  • GA-I cases in the Russian population were identified and described.
  • The disease often presents after infections with symptoms like seizures, vomiting, and coma.
  • Neurological complications include dystonias, dyskinesias, feeding difficulties, speech delay, and developmental delays.

Conclusions:

  • Glutaric aciduria type I requires prompt diagnosis through biochemical testing.
  • Management involves dietary protein restriction and carnitine supplementation.
  • Early intervention is critical to mitigate severe neurological sequelae.

More Related Videos

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure09:28

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure

Published on: June 25, 2010

Related Concept Videos

Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: